Navigation Links
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Date:10/28/2011

a rash or itching during treatment. These usually appear between treatments with ALIMTA and usually go away before the next treatment. Rarely, these reactions may be severe (can lead to Stevens-Johnson syndrome or toxic epidermal necrolysis) and could lead to death. Call your doctor if you get a severe rash, itching, or blistering.

Talk with your doctor, nurse, or pharmacist about any side effect that bothers you or that doesn't go away.

These are not all the side effects of ALIMTA. For more information, ask your doctor, nurse, or pharmacist.

How is ALIMTA given?

ALIMTA is slowly infused (injected) into a vein. The injection or infusion will last about 10 minutes. You will usually receive ALIMTA once every 21 days (3 weeks).

For more information about all of the side effects of ALIMTA, please talk with your healthcare team, see the Patient Prescribing Information and full Prescribing Information, visit www.ALIMTA.com, or call 1-800-545-5979.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This press release contains forward-looking statements about the potential of ALIMTA for the treatment of non-small cell lung cancer and reflects Lilly's current beliefs.  However, as with any pharmaceutical product under development, there are substantial risks and uncertainties in the process of development, commercialization, and regulatory review.  There is no guarantee that the product will receive additional regulatory approvals. There is also no guarantee that the product will continue to be commercially successfu
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
2. OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer
3. U.S. District Court Rules from Bench in Lillys Favor, Confirms Validity of Alimta Patent
4. Lung Cancer Study Reveals Similar Outcomes for African-American and Caucasian Patients Treated With Alimta®
5. ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
6. ALIMTA Helped Keep Most Common Form of Lung Cancer at Bay In Elderly Patients
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 Research and Markets ... Market by Equipment, by Reagent, by Application - Global ... http://photos.prnewswire.com/prnh/20130307/600769 Biopharmaceuticals ... is one of the most important and widely used ... application segment of the cell culture market in 2013. ...
(Date:7/22/2014)... Mass. , July 22, 2014  Decision ... audited multiple sclerosis (MS) patients currently treated ... Tecfidera have ever experienced flushing and/or gastrointestinal ... Tecfidera-treated patients are currently experiencing these side ... the effective medical management of such events. ...
(Date:7/22/2014)... 2014 The number of people overdosing from ... day. Twenty-three percent of the workforce has misused prescription ... and Health, making opioid use a serious threat to ... at the correct dosage with a valid prescription, subtle ... National Safety Council released a guide for ...
Breaking Medicine Technology:Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 35 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3
... Hospital today announced that revolutionary three-dimensional mammography imaging ... patient appointments at the Evergreen Breast Center, which ... Seattle area to offer the breakthrough screening and ... three-dimensional (3-D) digital imaging to create a complete ...
... Prescription drug spending growth slowed from an estimated ... according to new data released today by the Centers ... in Health Affairs. Researchers credit the slowdown in spending ... shifting medication use toward lower cost generic drugs. ...
Cached Medicine Technology:Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology 2Evergreen Hospital Launches Revolutionary Breast Cancer Detection and Diagnostic Imaging Technology 3PCMA: Study Credits PBM Tools with Reducing Prescription Drug Spending Growth 2
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Michael DeBaun, ... Robert P. Hebbel, MD, of the University of Minnesota ... Prize for their significant research advances in the area ... named for the late Ernest Beutler, MD, a past ... years, is a two-part lectureship that recognizes major translational ...
(Date:7/22/2014)... director of research at the University of Utah,s John ... International Society of Eye Research (ISER) as the recipient ... Kayser International Award in Retina Research., The award recognizes ... a significant contribution to the understanding of vitreoretinal diseases ... at the ISER Biennial Meeting in San Francisco, where ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Legislation ... Seniors Access to Local Pharmacies Act of 2014”) ... Part D would undermine the availability of lower ... by $21 billion over the next 10 years, ... released by the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... WASHINGTON -- Autoimmune disorders may share certain pathogenic mechanisms ... Washington University (GW) researcher Linda Kusner, Ph.D. , ... , This paradigm shifting work shows that the very ... are also expressed in cells that produce autoimmune diseases. ... of Neurology at the GW School of Medicine and ...
(Date:7/22/2014)... The Beryl Institute announces its fifth annual Patient ... These offerings reinforce the Institute’s commitment to support the ... the need for rigorous research to understand and address ... are intended to encourage and support research into ... the patient experience before, during and after care (e.g., ...
Breaking Medicine News(10 mins):Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 2Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 3Health News:Michael DeBaun, M.D., M.P.H., and Robert P. Hebbel, M.D., to present 2014 ASH Beutler Lecture 4Health News:University of Utah researcher Robert Marc receives Paul Kayser International Award 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3
... fluid in the middle ear, a condition called otitis media ... by antihistamines and decongestants, a new review of studies has ... in alleviating symptoms or avoiding complications of OME and expose ... ,"This review finds no benefit for any of the ...
... Virginia University professor and two alumni have tracked the ... the eye and often leads to blindness and death.// ... treatment for those who suffer from it. ,Joginder ... doctoral students Jason White ('02) and Alison Director-Myska ('96) ...
... Federal government of Australia came under the glaring critics ... its allocation of funds for various health promotion programs.// ... at the current government for lapses pertaining to health ... from rural medical facilities pharmaceuticals and after hour care ...
... the gut has been found to be an effective ... researchers at Cedars-Sinai Medical Center. ,The study ... the Annals of Internal Medicine It is the ... end of the course of treatment has ended. This ...
... reports that the board of the Central Gippsland Health Service ... ,Peter Goss and Jo McCubbin had resigned from the Sale ... such an action because of threats to services. However they ... place. ,In an open letter to the hospital board, ...
... Cancer’s exploits are titillated by personality traits, contemplates a ... rodents//. The idea that personality types may increase the ... ,Researchers at the University of Chicago ... point for cancer as compared to the rats that ...
Cached Medicine News:Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 2Health News:Allergy Drugs More Harmful Than Helpful for Chronic Ear Inflammation 3Health News:Team Tracks Genetic Origins of Eye Cancer 2Health News:Federal government blamed for allocating meager portion to health sector:ALP 2Health News:IBS Sufferers Benefited by Non-Absorbable Antibiotics 2
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
... Vitek is a completely automated instrument that ... 2 - 6 hour same day turnaround), ... control module. It is used for bacterial ... urine screening and has a complete data ...
IDS Rapid One, a microbial identification system....
The Cogent Microbial Luminescence System (MLS) is a superior Rapid microbial detection system for UHT product screening combining proven technology of ATP-bioluminescence with unsurpassed hardware in...
Medicine Products: